Rosuvastatin + Atorvastatin

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Coronary Atherosclerosis

Conditions

Coronary Atherosclerosis

Trial Timeline

Jan 1, 2008 → Jun 1, 2011

NCT ID

NCT00620542

About Rosuvastatin + Atorvastatin

Rosuvastatin + Atorvastatin is a phase 3 stage product being developed by AstraZeneca for Coronary Atherosclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00620542. Target conditions include Coronary Atherosclerosis.

What happened to similar drugs?

20 of 20 similar drugs in Coronary Atherosclerosis were approved

Approved (20) Terminated (2) Active (0)

✅EvolocumabHeartFlowApproved

✅Clopidogrel treatment groupYuhanApproved

✅high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibeYuhanApproved

✅statins, ezetimibe + Combination therapyYuhanApproved

✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved

✅PrasugrelDaiichi SankyoApproved

✅Prasugrel + ClopidogrelDaiichi SankyoApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (13)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00683618	Phase 3	Completed	May 1, 2008	Jul 1, 2009	Hypercholesterolemia
NCT00620542	Phase 3	Completed	Jan 1, 2008	Jun 1, 2011	Coronary Atherosclerosis
NCT00427960	Approved	Terminated	Dec 1, 2006	Feb 1, 2008	Hypercholesterolaemia
NCT00395486	Approved	Completed	Sep 1, 2006	Jun 1, 2008	Metabolic Syndrome X
NCT00296400	Phase 2	Completed	Feb 1, 2006	Jun 1, 2009	Hyperlipidemia
NCT00296387	Phase 3	Completed	Jan 1, 2006	Oct 1, 2007	Acute Coronary Syndrome
NCT00329173	Phase 3	Completed	Nov 1, 2003	Aug 1, 2004	Hypercholesterolaemia
NCT00239330	Phase 3	Completed	Jun 1, 2003	Feb 1, 2005	Hypercholesteremia
NCT00653965	Phase 3	Completed	May 1, 2003	Feb 1, 2005	Hypercholesterolemia
NCT00653588	Phase 3	Completed	Apr 1, 2003	Sep 1, 2004	Hypercholesterolemia
NCT00654225	Phase 3	Completed	Oct 1, 2002	Mar 1, 2005	Hypercholesterolemia
NCT00654485	Phase 3	Completed	May 1, 2002	Feb 1, 2005	Metabolic Syndrome
NCT00653744	Phase 3	Completed	Mar 1, 2002	Mar 1, 2004	Hypercholesterolemia

Competing Products

20 competing products in Coronary Atherosclerosis

See all competitors

Product	Company	Stage	Hype Score
Rosuvastatin 40mg + Placebo	HeartFlow	Pre-clinical	27
Evolocumab	HeartFlow	Approved	29
High intensity lipid lowering	HeartFlow	Pre-clinical	20
Exenatide	Eli Lilly	Phase 3	40
Clopidogrel treatment group	Yuhan	Approved	50
YH14659 + clopidogrel & aspirin	Yuhan	Phase 1	29
high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibe	Yuhan	Approved	43
Sarpogrelate + Aspirin + Clopidogrel + Placebo (for Sarpogrelate)	Yuhan	Phase 3	40
statins, ezetimibe + Combination therapy	Yuhan	Approved	50
YH14659 + clopidogrel & aspirin	Yuhan	Phase 1	29
Modification of Prasugrel based on a biological assay + prasugrel / clopidogrel	Daiichi Sankyo	Approved	43
clopidogrel + prasugrel	Daiichi Sankyo	Phase 1	21
Prasugrel	Daiichi Sankyo	Approved	43
ADP receptor inhibitors	Daiichi Sankyo	Pre-clinical	26
Pactimibe, CS-505	Daiichi Sankyo	Phase 2	35
Prasugrel + Clopidogrel	Daiichi Sankyo	Phase 2	35
prasugrel + clopidogrel	Daiichi Sankyo	Phase 1	29
Prasugrel + Clopidogrel	Daiichi Sankyo	Approved	43
Triple oral lipid lowering treatment	Daiichi Sankyo	Phase 3	47
Placebo + Prasugrel	Daiichi Sankyo	Phase 3	40